Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)

BACKGROUND: To establish the role of antiemetic therapy with neurokinin-1 (NK(1)) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.) fosaprepitant for the prevention of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Weinstein, C., Jordan, K., Green, S. A., Camacho, E., Khanani, S., Beckford-Brathwaite, E., Vallejos, W., Liang, L. W., Noga, S. J., Rapoport, B. L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2016
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4684151/
https://ncbi.nlm.nih.gov/pubmed/26449391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv482
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller